Nonmetastatic ypt0 rectal cancer after neoadjuvant treatment and total mesorectal excision: Lessons from a retrospective multicentric cohort of 383 patients.

Date publication

janvier 2022

Journal

Surgery

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LAKKIS Zaher

Tous les auteurs :
Collard MK, Rullier E, Panis Y, Karoui M, Benoist S, Tuech JJ, Alves A, Laforest A, Mege D, Cazelles A, Beyer-Berjot L, Christou N, Cotte E, Lakkis Z, O'Connell L, Parc Y, Piessen G, Lefevre JH,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35078629

Résumé

A better understanding of pathological features and oncological survival in ypT0 rectal cancer after neoadjuvant chemoradiotherapy is required to improve patient selection criteria for rectal-preserving approach by local excision. Our aim was to define risk of lymph node metastasis and oncological outcomes in ypT0 rectal cancer after chemoradiotherapy and total mesorectal excision.

Référence

Surgery. 2022 Jan 22;: